Changzhou Qianhong Biopharma CO.,LTD

002550

CNE100001070

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
5.83 ^CNY	-0.68%		-1.19%	-0.85%

Apr. 26	Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for the Year 2023	CI
Apr. 25	Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback Plan announced on April 15, 2023.

April 19, 2023 at 12:00 pm EDT

From April 13, 2023 to April 19, 2023, the company has repurchased 5,000,000 shares, representing 0.39% for CNY 30.09 million. With this, the company has completed the repurchase of 5,000,000 shares, representing 0.39% for CNY 30.09 million under the buyback announced on April 15, 2023.

Latest news about Changzhou Qianhong Biopharma CO.,LTD

Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for the Year 2023	Apr. 26	CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Tranche Update on Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback Plan announced on January 3, 2024.	Mar. 22	CI
Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback announced on January 3, 2024 has closed with 25,000,000 shares, representing 1.95% for CNY 140.76 million.	Mar. 21	CI
Changzhou Qianhong Biopharma CO.,LTD Approves Board Elections	Jan. 22	CI
Changzhou Qianhong Biopharma CO.,LTD announces an Equity Buyback for CNY 170 million worth of its shares.	Jan. 03	CI
Changzhou Qianhong Biopharma CO.,LTD authorizes a Buyback Plan.	Jan. 01	CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Changzhou Qianhong Biopharma CO.,LTD(XSEC:002550) added to S&P Global BMI Index	23-09-18	CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-21	CI
Changzhou Qianhong Biopharma Co.,Ltd Announces Cash Dividend on A Shares for 2022, Payable on May 26, 2023	23-05-18	CI
Changzhou Qianhong Biopharma CO.,LTD Approves Cash Dividend for 2022	23-05-12	CI
Tranche Update on Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback Plan announced on April 15, 2023.	23-04-19	CI
Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback announced on April 15, 2023 has closed with 5,000,000 shares, representing 0.39% for CNY 30.09 million.	23-04-18	CI
Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for 2022	23-04-17	CI
Changzhou Qianhong Biopharma CO.,LTD announces an Equity Buyback for CNY 34 million worth of its shares.	23-04-14	CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-14	CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Changzhou Qianhong Biopharma Co.,Ltd authorizes a Buyback Plan.	23-04-12	CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Qianhong Bio Pharma to Invest $85 Million in New Drug Production Base	22-09-22	MT
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-08	CI
Changzhou Qianhong Biopharma CO.,LTD Announces Final Cash Dividend on A Shares for the Year 2021, Payable on 25 May 2022	22-05-18	CI
Changzhou Qianhong Biopharma Co.,Ltd Approves Dividend for 2021	22-05-16	CI
Changzhou Qianhong Biopharma Co.,Ltd Proposes Distribution for 2021	22-04-25	CI

Chart Changzhou Qianhong Biopharma CO.,LTD

Duration

Period

Chart Changzhou Qianhong Biopharma CO.,LTD

More charts

Company Profile

Changzhou Qianhong Biopharma CO., LTD is a China-based company, principally engaged in the research and development, production and distribution of freeze-drying powder, freeze-drying powder injections, small volume injections, tablets, hard capsules, granules and bulk drugs, among others. The Company mainly provides liquaemin sodium raw materials and preparations, applied to prevent and treat thromboembolism desease; kallidinogen preparations, applied in the treatment of micro-circulation disorder disease, asparaginase bulk drugs and preparations, applied in the treatment of acute lymphoblastic leukemia, as well as compound digestive enzyme capsules II. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Changzhou Qianhong Biopharma CO.,LTD

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.83 CNY

Average target price

6.12 CNY

Spread / Average Target

+4.97%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHANGZHOU QIANHONG BIOPHARMA CO.,LTD	-0.85%	1.01B
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+34.65%	595B
JOHNSON & JOHNSON	-2.07%	369B
MERCK & CO., INC.	+20.25%	332B
ABBVIE INC.	+2.99%	282B
ASTRAZENECA PLC	+16.43%	244B
NOVARTIS AG	+9.79%	208B
ROCHE HOLDING AG	-4.54%	205B
AMGEN INC.	+7.43%	166B

Other Pharmaceuticals

Changzhou Qianhong Biopharma CO.,LTD

Equities

002550

CNE100001070

Pharmaceuticals

Tranche Update on Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback Plan announced on April 15, 2023.

Latest news about Changzhou Qianhong Biopharma CO.,LTD

Chart Changzhou Qianhong Biopharma CO.,LTD

Company Profile

Income Statement Evolution

Ratings for Changzhou Qianhong Biopharma CO.,LTD

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals